Prenetics lifts projected second-half loss to $30-35M, betting on IM8 growth
The Nasdaq-listed group more than triples its expected adjusted EBITDA loss to fund customer acquisition for IM8, while holding its full-year revenue range.
Prenetics Global is accepting a much deeper near-term loss to push its IM8 supplement brand. In its third-quarter 2026 shareholder letter, the company said it now expects an adjusted EBITDA loss of $30-35 million for the second half of the year. Its earlier range was $8-12 million, so the projected loss is about $22-23 million wider at both ends. Prenetics attributed the change to a decision to spend more on acquiring IM8 customers.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Prenetics Global Ltd ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.